

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
22 September 2005 (22.09.2005)

PCT

(10) International Publication Number
WO 2005/086663 A2

(51) International Patent Classification: **Not classified**

(21) International Application Number:
PCT/US2005/005820

(22) International Filing Date: 23 February 2005 (23.02.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/548,660 27 February 2004 (27.02.2004) US

(71) Applicant (for all designated States except US): **MERCK & CO., INC.** [US/US]; 126 East Lincoln Avenue, Rahway, New Jersey 07065-0907 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **ANDERSON, Annaliesa, S.** [GB/US]; 126 East Lincoln Avenue, Rahway, New Jersey 07065-0907 (US). **CLARK, Desmond, J.** [US/US]; 126 East Lincoln Avenue, Rahway, New Jersey 07065-0907 (US).

(74) Common Representative: **MERCK & CO., INC.**; 126 East Lincoln Avenue, Rahway, New Jersey 07065-0907 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

[Continued on next page]

(54) Title: POLYPEPTIDES FOR INDUCING A PROTECTIVE IMMUNE RESPONSE AGAINST STAPHYLOCOCCUS AUREUS

MRDKKGPVNKRVDFLSNKLNKYSIRKFTVGTASILIGSLMYLGTQQEAEAAENNIENPTTLK
DNVQSKEVKIEEVNTKDTAPQGVBAKSEVTSNKTIEHEPSVKAEDISKEDTPKEVADVAE
VQPKSSVTHNAETPKVRKARSDVDEGSFDITRDSKNVVESTPITIQQKEHFEGYGSVDIQKKP
TDLGVSEVTRFNVGNESNGLIGALQLKNKIDFSKDFNPKVRVANNHQSNTTGADGWGFLFSK
GNAEEYL/TNGGILGDKGLVNSGGFKIDTGYIYTSSMDKTEKQAGQGYRGYGAFAVKNDSSGNS
QMVGENIDKSKTNFLNYADNSTNTSDGKFHGRQLNDVILTYVASTGKMRAEYAGKTWETSIT
DLGLSKNQAYNFLITSSQRWGLNQGINANGWMRTDLKGSEFTFTPEAPKTITELEKKVEEIP
FKKERKFNPDLAPGTEKVTREGOKGEKTITPTLKNPLTGVIIISKGEPEKEEITKDPINELTE
YGPETIAPGHRDEFDPKLPTGEKEEVPGKPGIKNPETGDVVRPPVDSVTKYGPVKGDSIVEK
EEIPFEKERKFNPDLAPGTEKVTREGOKGEKTITPTLKNPLTGVIIISKGEPEKEEITKDPIN
ELTEYGPETITPGHRDEFDPKLPTGEKEEVPGKPGIKNPETGDVVRPPVDSVTKYGPVKGDS
IVEKEEIPFKKERKFNPDLAPGTEKVTREGOKGEKTITPTLKNPLTGEIISKGESKEEITK
DPINELTEYGPETITPGHRDEFDPKLPTGEKEEVPGKPGIKNPETGDVVRPPVDSVTKYGPV
KGDSIVEKEEIPFKKERKFNPDLAPGTEKVTREGOKGEKTITPTLKNPLTGEIISKGESKE
EITKDPINELTEYGPETITPGHRDEFDPKLPTGEKEEVPGKPGIKNPETGDVVRPPVDSVTK
YGPVKGDSIVEKEEIPFEKERKFNPDLAPGTEKVTREGOKGEKTITPTLKNPLTGEIISKG
ESKEEITKDPVNELTEFGGEKIPQGHKIDFDPNLPDQTEKVPKPGIKNPDTGKVIIEPVD
DVIKHGPKTGTPETKTVEIPFETKREFNPKLQPGEEVRKQEGQPGSKTITPTITVNPLTGEK
VGEGQPTIEITKQPVDKIVEFGGEKPKDKPGPENPEKPSRPHSGPVNPNNGLSKDRAKP
NGPVHSMKNDKVKKSKIAKESVANQEKKRAELPKTGLESTQKGLIFSSIIGIAGLMLLARR
RKN

(57) Abstract: The present invention features polypeptides comprising an amino acid sequence structurally related to SEQ ID NO: 1 and uses of such polypeptides. SEQ ID NO: 1 is a truncated derivative of a full length *S. aureus* polypeptide. The full-length polypeptide is referred to herein as full length "ORF0594". A His-tagged derivative of SEQ ID NO: 1 was found to produce a protective immune response against *S. aureus*.

WO 2005/086663 A2



For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

TITLE OF THE INVENTION

POLYPEPTIDES FOR INDUCING A PROTECTIVE IMMUNE RESPONSE AGAINST
STAPHYLOCOCCUS AUREUS

5 CROSS-REFERENCE TO RELATED APPLICATIONS

The present application claims the benefit of U.S. Provisional Application No. 60/548,660, filed February 27, 2004, which is hereby incorporated by reference herein.

BACKGROUND OF THE INVENTION

10 The references cited throughout the present application are not admitted to be prior art to the claimed invention.

Staphylococcus aureus is a pathogen responsible for a wide range of diseases and conditions. Examples of diseases and conditions caused by *S. aureus* include bacteremia, infective endocarditis, folliculitis, furuncle, carbuncle, impetigo, bullous impetigo, cellulitis, 15 botryomycosis, toxic shock syndrome, scalded skin syndrome, central nervous system infections, infective and inflammatory eye disease, osteomyelitis and other infections of joints and bones, and respiratory tract infections. (*The Staphylococci in Human Disease*, Crossley and Archer (eds.), Churchill Livingstone Inc. 1997.)

Immunological based strategies can be employed to control *S. aureus* infections 20 and the spread of *S. aureus*. Immunological based strategies include passive and active immunization. Passive immunization employs immunoglobulins targeting *S. aureus*. Active immunization induces immune responses against *S. aureus*.

Potential *S. aureus* vaccines target *S. aureus* polysaccharides and polypeptides. Targeting can be achieved using suitable *S. aureus* polysaccharides or polypeptides as vaccine 25 components. Examples of polysaccharides that may be employed as possible vaccine components include *S. aureus* type 5 and type 8 capsular polysaccharides. (*Shinefield et al., N. Eng. J. Med.* 346:491-496, 2002.) Examples of polypeptides that may be employed as possible vaccine components include collagen adhesin, fibrinogen binding proteins, and clumping factor. (Mamo *et al., FEMS Immunology and Medical Microbiology* 10:47-54, 1994, Nilsson *et al., J. Clin. Invest.* 101:2640-2649, 1998, Josefsson *et al., The Journal of Infectious Diseases* 184:1572-1580, 2001.) 30

Information concerning *S. aureus* polypeptide sequences has been obtained from sequencing the *S. aureus* genome. (Kuroda *et al., Lancet* 357:1225-1240, 2001, Baba *et al., Lancet* 359:1819-1827, 2000, Kunsch *et al., European Patent Publication EP 0 786 519*, 35 published July 30, 1997.) To some extent bioinformatics has been employed in efforts to

characterize polypeptide sequences obtained from genome sequencing. (Kunsch *et al.*, European Patent Publication EP 0 786 519, published July 30, 1997.)

Techniques such as those involving display technology and sera from infected patients have been used in an effort to identify genes coding for potential antigens. (Foster *et al.*, International Publication Number WO 01/98499, published December 27, 2001, Meinke *et al.*, International Publication Number WO 02/059148, published August 1, 2002, Etz *et al.*, *PNAS* 99:6573-6578, 2002.)

SUMMARY OF THE INVENTION

The present invention features polypeptides comprising an amino acid sequence structurally related to SEQ ID NO: 1 and uses of such polypeptides. SEQ ID NO: 1 is a truncated derivative of a full length *S. aureus* polypeptide. The full-length polypeptide is referred to herein as full length "ORF0594". A His-tagged derivative of SEQ ID NO: 1 was found to produce a protective immune response against *S. aureus*.

Reference to "protective" immunity or immune response indicates a detectable level of protection against *S. aureus* infection. The level of protection can be assessed using animal models such as those described herein.

Thus, a first aspect of the present invention describes a polypeptide immunogen consisting essentially of an amino acid sequence at least 90% identical to SEQ ID NO: 1.

Reference to consisting essentially of an amino acid sequence at least 90% identical to SEQ ID NO: 1 indicates that a SEQ ID NO: 1 related region is present and additional polypeptide regions up to about 100 amino acids also may be present.

A SEQ ID NO: 1 related region has at least about 90% sequence identity to SEQ ID NO: 1. Percent identity (also referred to as percent identical) to a reference sequence is determined by aligning the polypeptide sequence with the reference sequence and determining the number of identical amino acids in the corresponding regions. This number is divided by the total number of amino acids in the reference sequence (*e.g.*, SEQ ID NO: 1) and then multiplied by 100 and rounded to the nearest whole number.

Reference to "immunogen" indicates the ability to produce a protective immune response.

Another aspect of the present invention describes an immunogen comprising a polypeptide that provides protective immunity against *S. aureus* and one or more additional regions or moieties covalently joined to the polypeptide at the carboxyl terminus or amino terminus, wherein each region or moiety is independently selected from a region or moiety

having at least one of the following properties: enhances the immune response, facilitates purification, or facilitates polypeptide stability.

Reference to “additional region or moiety” indicates a region or moiety different from an ORF0594 region. The additional region or moiety can be, for example, an additional polypeptide region or a non-peptide region.

Another aspect of the present invention describes a composition able to induce protective immunity against *S. aureus* in a patient. The composition comprises a pharmaceutically acceptable carrier and an immunologically effective amount of a polypeptide that provides protective immunity against *S. aureus* or an immunogen containing the polypeptide.

An immunologically effective amount is an amount sufficient to provide protective immunity against *S. aureus* infection. The amount should be sufficient to significantly prevent the likelihood or severity of a *S. aureus* infection.

Another aspect of the present invention describes a nucleic acid comprising a recombinant gene encoding a polypeptide that provides protective immunity against *S. aureus*. A recombinant gene contains recombinant nucleic acid encoding a polypeptide along with regulatory elements for proper transcription and processing (which may include translational and post translational elements). The recombinant gene can exist independent of a host genome or can be part of a host genome.

A recombinant nucleic acid is nucleic acid that by virtue of its sequence and/or form does not occur in nature. Examples of recombinant nucleic acid include purified nucleic acid, two or more nucleic acid regions combined together that provides a different nucleic acid than found in nature, and the absence of one or more nucleic acid regions (*e.g.*, upstream or downstream regions) that are naturally associated with each other.

Another aspect of the present invention describes a recombinant cell. The cell comprises a recombinant gene encoding a polypeptide that provides protective immunity against *S. aureus*.

Another aspect of the present invention describes a method of making a polypeptide that provides protective immunity against *S. aureus*. The method involves growing a recombinant cell containing recombinant nucleic acid encoding the polypeptide and purifying the polypeptide.

Another aspect of the present invention describes a polypeptide that provides protective immunity against *S. aureus* made by a process comprising the steps of growing the recombinant cell containing recombinant nucleic acid encoding the polypeptide in a host and purifying the polypeptide. Different host cells can be employed.

Another aspect of the present invention describes a method of inducing a protective immune response in a patient against *S. aureus*. The method comprises the step of administering to the patient an immunologically effective amount of an immunogen providing protective immunity.

Unless particular terms are mutually exclusive, reference to “or” indicates either or both possibilities. Occasionally phrases such as “and/or” are used to highlight either or both possibilities.

Reference to open-ended terms such as “comprises” allows for additional elements or steps. Occasionally phrases such as “one or more” are used with or without open-ended terms to highlight the possibility of additional elements or steps.

Unless explicitly stated reference to terms such as “a” or “an” is not limited to one. For example, “a cell” does not exclude “cells”. Occasionally phrases such as one or more are used to highlight the possible presence of a plurality.

Other features and advantages of the present invention are apparent from the additional descriptions provided herein including the different examples. The provided examples illustrate different components and methodology useful in practicing the present invention. The examples do not limit the claimed invention. Based on the present disclosure the skilled artisan can identify and employ other components and methodology useful for practicing the present invention.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 illustrates the amino acid sequence of ORF0594 (SEQ ID NO: 3). Signal cleavage site (AA) is marked in italics, LPXTG is marked in bold, and non identical repeats are alternatively underlined or double underlined.

Figure 2 illustrates a sequence comparison between SEQ ID NOs: 2 and 3. SEQ ID NO: 2 is a His-tagged derivative of SEQ ID NO: 1. The region of SEQ ID NO: 3 providing SEQ ID NO: 1 is shown in bold.

Figure 3 illustrates survival data from 2 experiments using a SEQ ID NO:2 polypeptide (SEQ 2) in aluminum hydroxyphosphate adjuvant (AHP). A positive control SEQ 4 (SEQ ID NO: 4) was present in Exp. 1.

Figure 4 illustrates the amino acid sequence of SEQ ID NO: 4.

Figure 5 illustrates a nucleic acid sequence (SEQ ID NO: 5) encoding SEQ ID NO: 2. The bold region represents the start/stop -added during cloning. The underlined region represents the SEQ ID NO: 1 encoding region. The region not underlined represents the N-term His tag vector sequence.

DETAILED DESCRIPTION OF THE INVENTION

SEQ ID NO: 1 is identified herein as a sufficient polypeptide region to provide protective immunity against *S. aureus* infection. The ability of polypeptides structurally related to SEQ ID NO: 1 to provide protective immunity against *S. aureus* infection is illustrated using a His-Tag derivative of SEQ ID NO: 1. (See Examples *infra*.)

ORF0594 belongs to the LPXTG family of staphylococcal surface proteins. Sequence analysis of SEQ ID NO: 3 revealed the presence of several imperfect repeats at the carboxyl terminal end (Figure 1). SEQ ID NO: 1 was designed to encompass an entire non-identical repeat and a portion of the flanking sequences so that a suspected coil-coil structure could be maintained.

Figure 2 illustrates the sequences of SEQ ID NOs: 1, 2, and 3. SEQ ID NO: 1 is illustrated in Figure 2 as the bolded region of SEQ ID NO: 3. SEQ ID NO: 2 is an amino His-tag derivative of SEQ ID NO: 1. The His-tag facilitates polypeptide purification and identification.

SEQ ID NO: 1 Related Polypeptides

A polypeptide region structurally related to SEQ ID NO: 1 contains an amino acid identity of at least 90% to SEQ ID NO: 1. Polypeptides containing a region structurally related to SEQ ID NO: 1 can be designed based on the guidance provided herein to obtain polypeptides protective against *S. aureus*.

Polypeptides consisting essentially of a region structurally related to SEQ ID NO: 1 can also contain additional polypeptide regions that may or may not be related to ORF0594. ORF0594 related polypeptides are polypeptides having at least about 90% sequence identity to a corresponding region of a naturally occurring ORF0594. A reference ORF0594 is illustrated in Figure 1 (SEQ ID NO: 3).

Additional regions can be at the carboxyl or amino terminus of the SEQ ID NO: 1 related region. In different embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, up to 25 or up to 50 additional amino acids are present; an amino terminus methionine is present; and/or the additional amino acids are ORF0594 related polypeptide regions.

Using SEQ ID NO: 1 as a frame of reference, alterations can be made taking into account the known properties of amino acids. Alterations include one or more amino acid additions, deletions, and/or substitutions. The overall effect of different alterations can be evaluated using techniques described herein to confirm the ability of a particular polypeptide to provide protective immunity.

Generally, in substituting different amino acids to retain activity it is preferable to exchange amino acids having similar properties. Factors that can be taken into account for an amino acid substitution include amino acid size, charge, polarity, and hydrophobicity. The effect of different amino acid R-groups on amino acid properties are well known in the art. (See, for example, Ausubel, *Current Protocols in Molecular Biology*, John Wiley, 1987-2002, Appendix 1C.)

In exchanging amino acids to maintain activity, the replacement amino acid should have one or more similar properties such as approximately the same charge and/or size and/or polarity and/or hydrophobicity. For example, substituting valine for leucine, arginine for lysine, and asparagine for glutamine are good candidates for not causing a change in polypeptide functioning.

Alterations to achieve a particular purpose include those designed to facilitate production or efficacy of the polypeptide; or cloning of the encoded nucleic acid. Polypeptide production can be facilitated through the use of an initiation codon (e.g., coding for methionine) suitable for recombinant expression. The methionine may be later removed during cellular processing. Cloning can be facilitated by, for example, the introduction of restriction sites which can be accompanied by amino acid additions or changes.

Efficacy of a polypeptide to induce an immune response can be enhanced through epitope enhancement. Epitope enhancement can be performed using different techniques such as those involving alteration of anchor residues to improve peptide affinity for MHC molecules and those increasing affinity of the peptide-MHC complex for a T-cell receptor. (Berzofsky *et al.*, *Nature Review* 1:209-219, 2001.)

A polypeptide region at least about 90% identical to SEQ ID NO: 1 contains up to about 19 amino acid alterations from SEQ ID NO: 1. In different embodiments, the SEQ ID NO: 1 related polypeptide is at least 90%, at least 95%, or at least 99% identical to SEQ ID NO: 1; or differs from SEQ ID NO: 1 by 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, or 19 amino acid alterations. Each amino acid alteration is independently an addition, deletion or substitution.

Longer length derivatives can be produced, for example, taking into account additional sequence information provided in SEQ ID NO: 3 or other naturally occurring proteins corresponding to SEQ ID NO: 3.

Preferably, the polypeptide is a purified polypeptide. A "purified polypeptide" is present in an environment lacking one or more other polypeptides with which it is naturally associated and/or is represented by at least about 10% of the total protein present. In different

embodiments, the purified polypeptide represents at least about 50%, at least about 75%, or at least about 95% of the total protein in a sample or preparation.

In an embodiment, the polypeptide is “substantially purified”. A substantially purified polypeptide is present in an environment lacking all, or most, other polypeptides with which the polypeptide is naturally associated. For example, a substantially purified *S. aureus* polypeptide is present in an environment lacking all, or most, other *S. aureus* polypeptides. An environment can be, for example, a sample or preparation.

Reference to “purified” or “substantially purified” does not require a polypeptide to undergo any purification and may include, for example, a chemically synthesized polypeptide that has not been purified.

Polypeptide stability can be enhanced by modifying the polypeptide carboxyl or amino terminus. Examples of possible modifications include amino terminus protecting groups such as acetyl, propyl, succinyl, benzyl, benzyloxycarbonyl or *t*-butyloxycarbonyl; and carboxyl terminus protecting groups such as amide, methylamide, and ethylamide.

An embodiment of the present invention describes an immunogen consisting of a protective polypeptide and one or more additional regions or moieties covalently joined to the polypeptide at the carboxyl terminus or amino terminus. Each region or moiety should be independently selected from a region or moiety having at least one of the following properties: enhances the immune response, facilitates purification, or facilitates polypeptide stability. Polypeptide stability can be enhanced, for example, using groups such as polyethylene glycol that may be present on the amino or carboxyl terminus.

Polypeptide purification can be enhanced by adding a group to the carboxyl or amino terminus to facilitate purification. Examples of groups that can be used to facilitate purification include polypeptides providing affinity tags. Examples of affinity tags include a six-histidine tag, trpE, glutathione and maltose-binding protein.

The ability of a polypeptide to produce an immune response can be enhanced using groups that generally enhance an immune response. Examples of groups that can be joined to a polypeptide to enhance an immune response against the polypeptide include cytokines such as IL-2. (Buchan *et al.*, 2000. *Molecular Immunology* 37:545-552.)

Polypeptide Production

Polypeptides can be produced using standard techniques including those involving chemical synthesis and those involving purification from a cell producing the polypeptide. Techniques for chemical synthesis of polypeptides are well known in the art. (See *e.g.*, Vincent, *Peptide and Protein Drug Delivery*, New York, N.Y., Decker, 1990.)

Techniques for polypeptide purification from a cell are illustrated in the Examples provided below. Additional examples of purification techniques are well known in the art. (See for example, Ausubel, *Current Protocols in Molecular Biology*, John Wiley, 1987-2002.)

Obtaining polypeptides from a cell is facilitated using recombinant nucleic acid techniques to produce the polypeptide. Recombinant nucleic acid techniques for producing a polypeptide involve introducing, or producing, a recombinant gene encoding the polypeptide in a cell and expressing the polypeptide.

A recombinant gene contains nucleic acid encoding a polypeptide along with regulatory elements for polypeptide expression. The recombinant gene can be present in a cellular genome or can be part of an expression vector.

The regulatory elements that may be present as part of a recombinant gene include those naturally associated with the polypeptide encoding sequence and exogenous regulatory elements not naturally associated with the polypeptide encoding sequence. Exogenous regulatory elements such as an exogenous promoter can be useful for expressing a recombinant gene in a particular host or increasing the level of expression. Generally, the regulatory elements that are present in a recombinant gene include a transcriptional promoter, a ribosome binding site, a terminator, and an optionally present operator. A preferred element for processing in eukaryotic cells is a polyadenylation signal.

Expression of a recombinant gene in a cell is facilitated through the use of an expression vector. Preferably, an expression vector in addition to a recombinant gene also contains an origin of replication for autonomous replication in a host cell, a selectable marker, a limited number of useful restriction enzyme sites, and a potential for high copy number. Examples of expression vectors are cloning vectors, modified cloning vectors, specifically designed plasmids and viruses.

Due to the degeneracy of the genetic code, a large number of different encoding nucleic acid sequences can be used to code for a particular polypeptide. The degeneracy of the genetic code arises because almost all amino acids are encoded by different combinations of nucleotide triplets or "codons". Amino acids are encoded by codons as follows:

A=Ala=Alanine: codons GCA, GCC, GCG, GCU

C=Cys=Cysteine: codons UGC, UGU

D=Asp=Aspartic acid: codons GAC, GAU

E=Glu=Glutamic acid: codons GAA, GAG

F=Phe=Phenylalanine: codons UUC, UUU

G=Gly=Glycine: codons GGA, GGC, GGG, GGU

H=His=Histidine: codons CAC, CAU

I=Ile=Isoleucine: codons AUA, AUC, AUU

K=Lys=Lysine: codons AAA, AAG

L=Leu=Leucine: codons UUA, UUG, CUA, CUC, CUG, CUU

M=Met=Methionine: codon AUG

5 N=Asn=Asparagine: codons AAC, AAU

P=Pro=Proline: codons CCA, CCC, CCG, CCU

Q=Gln=Glutamine: codons CAA, CAG

R=Arg=Arginine: codons AGA, AGG, CGA, CGC, CGG, CGU

S=Ser=Serine: codons AGC, AGU, UCA, UCC, UCG, UCU

10 T=Thr=Threonine: codons ACA, ACC, ACG, ACU

V=Val=Valine: codons GUA, GUC, GUG, GUU

W=Trp=Tryptophan: codon UGG

Y=Tyr=Tyrosine: codons UAC, UAU

Suitable cells for recombinant nucleic acid expression of ORF0594 related

15 polypeptides are prokaryotes and eukaryotes. Examples of prokaryotic cells include *E. coli*; members of the *Staphylococcus* genus, such as *S. aureus*; members of the *Lactobacillus* genus, such as *L. plantarum*; members of the *Lactococcus* genus, such as *L. lactis*; and members of the *Bacillus* genus, such as *B. subtilis*. Examples of eukaryotic cells include mammalian cells; insect cells; yeast cells such as members of the *Saccharomyces* genus (*e.g.*, *S. cerevisiae*), members of the *Pichia* genus (*e.g.*, *P. pastoris*), members of the *Hansenula* genus (*e.g.*, *H. polymorpha*),
20 members of the *Kluyveromyces* genus (*e.g.*, *K. lactis* or *K. fragilis*) and members of the *Schizosaccharomyces* genus (*e.g.*, *S. pombe*).

Techniques for recombinant gene production, introduction into a cell, and recombinant gene expression are well known in the art. Examples of such techniques are
25 provided in references such as Ausubel, *Current Protocols in Molecular Biology*, John Wiley, 1987-2002, and Sambrook *et al.*, *Molecular Cloning, A Laboratory Manual*, 2nd Edition, Cold Spring Harbor Laboratory Press, 1989.

If desired, expression in a particular host can be enhanced through codon optimization. Codon optimization includes use of more preferred codons. Techniques for codon
30 optimization in different hosts are well known in the art.

Depending upon the host used for expression, ORF0594 related polypeptides may contain post translational modifications. Reference to "polypeptide" or an "amino acid" sequence of a polypeptide includes polypeptides containing one or more amino acids having a structure of a post-translational modification from a host cell, such as a yeast host.

For example, in *S. cerevisiae*, the nature of the penultimate amino acid appears to determine whether the N-terminal methionine is removed. Furthermore, the nature of the penultimate amino acid also determines whether the N-terminal amino acid is N^α-acetylated (Huang *et al.*, *Biochemistry* 26: (1987), 8242-8246, 1987). Thus, within the scope of this invention, the ORF0594-related polypeptide may have an N^α-acetylated N-terminus and the N-terminal methionine may be removed, depending on which amino acid is in the penultimate position.

In addition, if the ORF0594-related polypeptide is targeted for secretion due to the presence of a secretory leader (*e.g.*, signal peptide), the protein may be modified by N-linked or O-linked glycosylation. (Kukuruzinska *et al.*, *Ann. Rev. Biochem.* 56:915-944, 1987.)

Adjuvants

Adjuvants are substances that can assist an immunogen in producing an immune response. Adjuvants can function by different mechanisms such as one or more of the following: increasing the antigen biologic or immunologic half-life; improving antigen delivery to antigen-presenting cells; improving antigen processing and presentation by antigen-presenting cells; and inducing production of immunomodulatory cytokines. (Vogel, *Clinical Infectious Diseases* 30(suppl. 3):S266-270, 2000.)

A variety of different types of adjuvants can be employed to assist in the production of an immune response. Examples of particular adjuvants include aluminum hydroxide, aluminum phosphate, or other salts of aluminum, calcium phosphate, DNA CpG motifs, monophosphoryl lipid A, cholera toxin, *E. coli* heat-labile toxin, pertussis toxin, muramyl dipeptide, Freund's incomplete adjuvant, MF59, SAF, immunostimulatory complexes, liposomes, biodegradable microspheres, saponins, nonionic block copolymers, muramyl peptide analogues, polyphosphazene, synthetic polynucleotides, IFN- γ , IL-2 and IL-12. (Vogel *Clinical Infectious Diseases* 30(suppl 3):S266-270, 2000, Klein *et al.*, *Journal of Pharmaceutical Sciences* 89:311-321, 2000.)

Patients For Inducing Protective Immunity

A "patient" refers to a mammal capable of being infected with *S. aureus*. A patient can be treated prophylactically or therapeutically. Prophylactic treatment provides sufficient protective immunity to reduce the likelihood, or severity, of a *S. aureus* infection. Therapeutic treatment can be performed to reduce the severity of a *S. aureus* infection.

Prophylactic treatment can be performed using a vaccine containing an immunogen described herein. Such treatment is preferably performed on a human. Vaccines can

be administered to the general population or to those persons at an increased risk of *S. aureus* infection.

Persons with an increased risk of *S. aureus* infection include health care workers; hospital patients; patients with a weakened immune system; patients undergoing surgery; patients receiving foreign body implants, such a catheter or a vascular device; patients facing therapy leading to a weakened immunity; and persons in professions having an increased risk of burn or wound injury. (*The Staphylococci in Human Disease*, Crossley and Archer (ed.), Churchill Livingstone Inc. 1997.)

Non-human patients that can be infected with *S. aureus* include cows, pigs, sheep, goats, rabbits, horses, dogs, cats and mice. Treatment of non-human patients is useful in protecting pets and livestock, and in evaluating the efficacy of a particular treatment.

Combination Vaccines

ORF0594 related polypeptides providing protective immunity can be used alone, or in combination with other immunogens, to induce an immune response. Additional immunogens that may be present include: one or more additional *S. aureus* immunogens, such as those referenced in the Background of the Invention *supra*; one or more immunogens targeting one or more other *Staphylococcus* organisms such as *S. epidermidis*, *S. haemolyticus*, *S. warneri*, or *S. lugunensis*; and one or more immunogens targeting other infectious organisms.

Animal Model System

An animal model system was used to evaluate the efficacy of a polypeptide to produce a protective immune response against *Staphylococcus*. Two obstacles encountered in setting up a protective animal model were: (1) very high challenge dose needed to overcome innate immunity and (2) death rate too fast to detect a protective response. Specifically, after bacterial challenge mice succumbed to infection within 24 hours which did not provide sufficient time for the specific immune responses to resolve the infection. If the dose was lowered both control and immunized mice survived the infection.

These obstacles were addressed by using a slow kinetics lethality model involving *S. aureus* prepared from cells in stationary phase, appropriately titrated, and intravenously administered. This slow kinetics of death provides sufficient time for the specific immune defense to fight off the bacterial infection (*e.g.*, 10 days rather 24 hours).

S. aureus cells in stationary phase can be obtained from cells grown on solid medium. They can also be obtained from liquid, however the results with cells grown on solid media were more reproducible. Cells can conveniently be grown overnight on solid medium.

For example, *S. aureus* can be grown from about 18 to about 24 hours under conditions where the doubling time is about 20-30 minutes.

S. aureus can be isolated from solid or liquid medium using standard techniques to maintain *Staphylococcus* potency. Isolated *Staphylococcus* can be stored, for example, at
5 -70°C as a washed high density suspension ($> 10^9$ colony forming units (CFU)/mL) in phosphate buffered saline containing glycerol.

The *Staphylococcus* challenge should have a potency providing about 80 to 90% death in an animal model over a period of about 7 to 10 days starting on the first or second day. Titration experiments can be performed using animal models to monitor the potency of the stored
10 *Staphylococcus* inoculum. The titration experiments can be performed about one to two weeks prior to an inoculation experiment.

Initial potency for titration experiments can be based on previous experiments. For *S. aureus* and the animal model strain Becker a suitable potency was generally found in the range of 5×10^8 to 8×10^8 CFU/ml.
15

Administration

Immunogens can be formulated and administered to a patient using the guidance provided herein along with techniques well known in the art. Guidelines for pharmaceutical administration in general are provided in, for example, *Vaccines* Eds. Plotkin and Orenstein,
20 W.B. Sanders Company, 1999; *Remington's Pharmaceutical Sciences 20th Edition*, Ed. Gennaro, Mack Publishing, 2000; and *Modern Pharmaceutics 2nd Edition*, Eds. Banker and Rhodes, Marcel Dekker, Inc., 1990, each of which are hereby incorporated by reference herein.

Pharmaceutically acceptable carriers facilitate storage and administration of an immunogen to a patient. Pharmaceutically acceptable carriers may contain different components
25 such as a buffer, sterile water for injection, normal saline or phosphate buffered saline, sucrose, histidine, salts and polysorbate.

Immunogens can be administered by different routes such as subcutaneous, intramuscular, or mucosal. Subcutaneous and intramuscular administration can be performed using, for example, needles or jet-injectors.

Suitable dosing regimens are preferably determined taking into account factors well known in the art including age, weight, sex and medical condition of the patient; the route of administration; the desired effect; and the particular compound employed. The immunogen can be used in multi-dose vaccine formats. It is expected that a dose would consist of the range of
30 1.0 µg to 1.0 mg total polypeptide, in different embodiments of the present invention the range is
35 0.01 mg to 1.0 mg and 0.1 mg to 1.0 mg.

The timing of doses depends upon factors well known in the art. After the initial administration one or more booster doses may subsequently be administered to maintain or boost antibody titers. An example of a dosing regime would be day 1, 1 month, a third dose at either 4, 6 or 12 months, and additional booster doses at distant times as needed.

5

Generation of Antibodies

An ORF0594 related polypeptide able to induce protective immunity can be used to generate antibodies and antibody fragments that bind to the polypeptide or to *S. aureus*. Such antibodies and antibody fragments have different uses including use in polypeptide purification, *S. aureus* identification, or in therapeutic or prophylactic treatment against *S. aureus* infection.

10

Antibodies can be polyclonal or monoclonal. Techniques for producing and using antibodies are well known in the art. Examples of such techniques are described in Ausubel, *Current Protocols in Molecular Biology*, John Wiley, 1987-1998, Harlow *et al.*, *Antibodies, A Laboratory Manual*, Cold Spring Harbor Laboratory, 1988, and Kohler *et al.*, *Nature* 256:495-497, 1975.

15

EXAMPLES

Examples are provided below further illustrating different features of the present invention. The examples also illustrate useful methodology for practicing the invention. These examples do not limit the claimed invention.

20

Example 1: Use of a SEQ ID NO: 1 Region to Provide Protective Immunity

This example illustrates the ability of a SEQ ID NO: 1 polypeptide region to provide protective immunity in an animal model. The SEQ ID NO: 1 region was part of a His-tagged polypeptide having the amino acid sequence of SEQ ID NO: 3.

25

ORF0594 Cloning and Expression and Modification

An ORF0594 DNA sequence was translated using Vector NTI software and the resulting 1243 amino acid sequence was analyzed. PCR primers were designed to amplify the gene starting at the first asparagine residue and ending prior to the stop codon at the terminal asparagine residue. These PCR primers also had additional NcoI (forward primer) and XhoI (reverse primer) sites to facilitate cloning into the expression vector.

30

The protein was designed to be expressed from the pET28 vector with the terminal His residues and the stop codon encoded by the vector. In addition, a glycine residue

was added to the protein after the methionine initiator. The resulting amplified (3735bp) DNA sequence encodes a 1245 amino acid mutated form of mature ORF0594.

PCR amplified sequences were ligated into the pET28 vector (Novagen) using the NcoI/XhoI sites that had been engineered into the PCR primers and introduced into *E. coli* DH5 α (Invitrogen) by heat shock. No colonies were obtained.

The protein was further analyzed and non-identical repeat regions were identified at the Carboxyl-terminus. PCR primers were designed to amplify a completed non-identical repeat. Additional amino and carboxyl terminal sequences were also included so as to help the protein achieve a native confirmation.

PCR amplified sequences were ligated into the pET30 vector (Novagen) using the NcoI/XhoI sites that had been engineered into the PCR primers and introduced into *E. coli* DH5 α (Invitrogen) by heat shock. Colonies were selected, grown in LB with 30 μ g/mL kanamycin, DNA minipreps made (Promega), and insert integrity determined by restriction digestion and PCR. Four minipreps with correct insert size were sequenced using the primers listed in Table 1. A clone was selected containing no DNA changes from the desired sequence. The resulting clone expressed in the pET30 vector (Novagen) contains an N-terminal His tag with 46 residues and a stop codon encoded by the vector.

Table 1

SEQ ID NO:	Description	Sequence
6	ORF594F	ACCGGTTCCATATGAGAGATAAGAAAGGACCGGT
7	ORF594R	CCGGCGGCCCTCGAGATTCTTTCTTCTACGAGCCAATAAC
8	ORF594-AF	GAGATATACCATGGGCAGAACTGACTTGAAAGGTTTCAGA
9	ORF594-AR	CCGGCGGCCCTCGAGTTATGTCGTTATTGTCTTCTCACCT

E. coli HMS174(DE3) cells (Novagen) were transformed and grown on LB plates containing kanamycin (30ug/ml); 3 colonies were selected for expression testing. Liquid LB (kanamycin) cultures were incubated at 37°C, 250 rpm until the A₆₀₀ was between 0.6 and 1.0 and then induced by the addition of IPTG to final concentrations of 1 mM followed by three hours further incubation. Cultures were harvested by centrifugation at 5000 x g for 5 minutes at 4°C. Cells were resuspended in 500 μ l lysis buffer (Bug Buster, with protease inhibitors, Novagen). An equal volume of loading buffer (supplemented with β -mecapto ethanol to 5% final volume) was added prior to heating the samples at 70°C for 5 minutes. Extracts were run on Novex 4-20% Tris-Glycine gels and assayed for protein (Coomassie Blue stained) and blotted onto nitrocellulose and probed with anti-HIS6 antibodies (Zymedd).

Polypeptide Purification

Recombinant *E. coli* cells (39 grams wet cell weight) were suspended in Lysis Buffer (50 mM sodium phosphate, pH 8.0, 0.15 M NaCl, 2 mM MgCl₂, 10 mM imidazole, 0.1% TweenTM-80, and 0.02% sodium azide) at 3.7 ml per gram of cell wet weight. Protease Inhibitor Cocktail for use with poly-(Histidine)-tagged proteins (Roche #1873580) was added to the suspension at 1 tablet per 15 grams of cell paste. BenzonaseTM (EM Ind.) was added to 1 µL/mL. Cell lysis was accomplished by passing the suspension through a microfluidizer at 14,000 PSI (Microfluidics Model 110S) three times. The cell suspension was cooled on ice between each pass so that the temperature remained below 25°C. Cell debris was pelleted at 11,000 x g for 30 minutes at 4°C, and the supernatant retained.

Proteins bearing a His-tag were purified from the supernatant. The supernatant was mixed with 12 mL of Ni²⁺-NTA agarose (Qiagen) at 4°C with gentle inversion for 18 hours. The mixture was poured into an open column (1.5 cm x 20 cm) and the non-bound fraction was collected in bulk. The column was washed with Wash Buffer (50 mM sodium phosphate, pH 8.0, 0.3 M NaCl, 20 mM imidazole, and 0.1% TweenTM-80). His-tagged protein was eluted with a step gradient of 300 mM imidazole, 20 mM Tris-HCl, pH 8, 0.3 M NaCl, 0.1% TweenTM-80.

Fractions containing ORF0594 protein were detected by Coomassie stained SDS-PAGE and pooled. Pooled fractions were filtered through a 0.2 micron filter to remove particulate material, and were applied on a size-exclusion column (Sephacryl S-300 26/60 column, Amersham Biosciences) and eluted at 1 mL/min with 30 mM MOPS pH 7.0, 0.3 M NaCl, and 10% glycerol. Fractions containing ORF0594 were detected by Coomassie stained SDS-PAGE and Western blotting (anti-tetra His Mab, Qiagen). Protein was determined by BCA (Pierce). Purity was determined by densitometry of Coomassie stained gels.

Preparation of S. Aureus Challenge

S. aureus was grown on TSA plates at 37°C overnight. The bacteria were washed from the TSA plates by adding 5 ml of PBS onto a plate and gently resuspending the bacteria with a sterile spreader. The bacterial suspension was spun at 6000 rpm for 20 minutes using a Sorvall RC-5B centrifuge (DuPont Instruments). The pellet was resuspended in 16% glycerol and aliquots were stored frozen at -70°C.

Prior to use, inocula were thawed, appropriately diluted and used for infection. Each stock was titrated at least 3 times to determine the appropriate dose inducing slow kinetics of death in naive mice. The potency of the bacterial inoculum (80 to 90% lethality) was constantly monitored to assure reproducibility of the model. Ten days before each challenge

experiment, a group of 10 control animals (immunized with adjuvant alone) were challenged and monitored.

Protection Studies for a SEQ ID NO: 2 Polypeptide

5 Twenty BALB/c mice were immunized with three doses of a SEQ ID NO: 2 polypeptide (20 µg per dose) on aluminum hydroxyphosphate adjuvant (450 µg per dose). Aluminum hydroxyphosphate adjuvant (AHP) is described by Klein *et al.*, *Journal of Pharmaceutical Sciences* 89:311-321, 2000. The doses were administered as two 50 µl injections on days 0, 7 and 21. The mice were bled on day 28, and their sera were screened by
10 ELSIA for reactivity to the SEQ ID NO: 2 polypeptide. On day 35 of the experiment the mice were challenged by intravenous injection of *S. aureus* grown at a dose (10^8 CFU ml). The mice were monitored over a 10 day period for survival.

Two different sets of experiments were performed to measure the ability of a SEQ ID NO: 1 related peptide to provide protective immunity. In the first experiment, an immunogen
15 of SEQ ID NO: 4 in AHP was used as a positive control. The positive control was administered at 10 µg per dose in the same manner as the SEQ ID NO: 2 polypeptide. A second experiment was performed without a positive control. The results of the both experiments are shown in Figure 3.

The employed animal model is very extreme due to the high dose of bacteria
20 administered and the size of the animal, and has some variability. In human disease, infection is initiated by a reduced bacterial load. Modest protection of immunogen with the employed animal model provides support for the effectiveness of a vaccine in humans.

In the first experiment, 7 mice from the SEQ ID NO: 2 polypeptide immunized group survived compared to 3 surviving in the AHP control group and 11 surviving from the
25 SEQ ID NO: 4 immunized group. The results from the first experiment indicate that SEQ ID NO: 2 polypeptide is moderately protective.

In the second experiment, an equal number of mice survived that were immunized with the SEQ ID NO: 2 polypeptide compared to mice surviving in the AHP group. However, the second experiment did not contain a positive control. Thus, the results of the second experiment
30 are suspect compared to the first experiment.

Other embodiments are within the following claims. While several embodiments have been shown and described, various modifications may be made without departing from the spirit and scope of the present invention.

WHAT IS CLAIMED IS:

1. A polypeptide immunogen consisting essentially of an amino acid sequence at least 90% identical to SEQ ID NO: 1, wherein said polypeptide provides protective immunity against *S. aureus*.
5
2. The polypeptide of claim 1, wherein said polypeptide consists of an amino acid sequence at least 90% identical to SEQ ID NO: 1.
3. The polypeptide of claim 2, wherein said polypeptide consists of an amino acid sequence at least 94% identical to SEQ ID NO: 1.
10
4. The polypeptide of claim 3, wherein said polypeptide consists of an amino acid sequence of SEQ ID NO: 1.
15
5. An immunogen consisting of the polypeptide of claim 1 and one or more additional regions moieties covalently joined to said polypeptide at the carboxyl terminus or amino terminus, wherein each region or moiety is independently selected from a region or moiety having at least one of the following properties: enhances the immune response, facilitates purification, or facilitates polypeptide stability.
20
6. A composition able to induce a protective immune response in a patient comprising an immunologically effective amount of the immunogen of any one of claims 1-5 and a pharmaceutically acceptable carrier.
25
7. The composition of claim 6, wherein said composition further comprises an adjuvant.
8. A nucleic acid comprising a recombinant gene comprising a nucleotide sequence encoding the polypeptide of any one of claims 1-4.
30
9. The nucleic acid of claim 8, wherein said nucleic acid is an expression vector.

10. A recombinant cell comprising a recombinant gene comprising a nucleotide sequence encoding the polypeptide of any one of claims 1-4.

11. A method of making a *S. aureus* polypeptide that provides protective immunity comprising the steps of:

(a) growing the recombinant cell of claim 10 under conditions wherein said polypeptide is expressed; and

(b) purifying said polypeptide.

12. A method of inducing a protective immune response in a patient comprising the step of administering to said patient an immunologically effective amount of an immunogen comprising a polypeptide consisting essentially of an amino acid sequence at least 90% identical to SEQ ID NO: 1, and said polypeptide provides protective immunity against *S. aureus*.

13. The method of claim 12, wherein said immunogen is the immunogen of any one of claims 1-5.

14. The method of claim 13, wherein said patient is a human.

15. The method of claim 14, wherein said patient is treated prophylactically against *S. aureus* infection.

16. A method of inducing a protective immune response in a patient comprising the step of administering to said patient an immunologically effective amount of a polypeptide made by the method of claim 11.

MRDKKGPVNKRVDFLSNKLNKYSIRKFTVGTASILIGSLMYLGTQQEAEAAENNIENPTTLK
DNVQSKEVKIEEVTNKDTAPQGVAKSEVTSNKDTIEHEPSVKAEDISKKEDTPKEVADVAE
VQPKSSVTHNAETPKVRKARSVDEGSFDITRDSKNVVESTPIITIQGKEHFEGYGSVDIQKKP
TDLGVSEVTRFNVGNESNGLIGALQLKNKIDFSKDFNFKVRVANNHQSNTTGADGWGFLFSK
GNAEEYLTNGGILGDKGLVNSGGFKIDTGYYTSSMDKTEKQAGQGYRGYGAFVKNDSSGNS
QMVGENIDKSKTNFLNYADNSTNTSDGKFHGQRLNDVILTYVASTGKMRAEYAGKTWETSIT
DLGLSKNQAYNFLITSSQRWGLNQGINANGWMRTDLKGSEFTFTPEAPKTITELEKKVEEIP
FKKERKFNPDLAPGTEKVTREGOKGEKTITPTLKNPLTGVIISKGEPKEEITKDPINELTE
YGPETIAPGHRDEFDPKLPTGEKEEVPKGKPGIKNPETGDVVRPPVDSVTKYGPVKGDSIVEK
EEIPFEKERKFNPDLAPGTEKVTREGOKGEKTITPTLKNPLTGVIISKGEPKEEITKDPIN
ELTEYGPETITPGHRDEFDPKLPTGEKEEVPKGKPGIKNPETGDVVRPPVDSVTKYGPVKGDS
IVEKEEIPFKKERKFNPDLAPGTEKVTREGOKGEKTITPTLKNPLTGEIISKGESKEEITK
DPINELTEYGPETITPGHRDEFDPKLPTGEKEEVPKGKPGIKNPETGDVVRPPVDSVTKYGPV
KGDSIVEKEEIPFKKERKFNPDLAPGTEKVTREGOKGEKTITPTLKNPLTGEIISKGESKE
EITKDPINELTEYGPETITPGHRDEFDPKLPTGEKEEVPKGKPGIKNPETGDVVRPPVDSVTK
YGPVKGDSIVEKEEIPFEKERKFNPDLAPGTEKVTREGOKGEKTITPTLKNPLTGEIISKG
ESKEEITKDPVNELTEFGGEKIPQGHKIDFDPNLPTDQTEKVPKGKPGIKNPDTGKVIEEPVD
DVIKHGPKTGTPETKTVEIPFETKREFNPKLQPGEEVRVKQEGQPGSKTITPTITVNPLTGEK
VGEGQPTTEEITKQPVDKIVEFGGEKPKDPKGPENPEKPSRPTHPSGPVNPNNPGLSKDRAKP
NGPVHSMDKNDKVKKSKIAKESVANQEKKRAEL**PKTG**LESTQKGLIFSSIIGIAGLMLLARR
RKN

FIG. 1

2/4

```

SEQ ID NO: 2 -----
SEQ ID NO: 3 MRDKKGPVNKRVDFLSNKLNKYSIRKFTVGTASILIGSLMYLGTQQEAEAAENNIENPTT

SEQ ID NO: 2 -----
SEQ ID NO: 3 LKDNVQSKEVKIEEVTNKDTAPQGVEAKSEVTSNKDTIEHEPSVKAEDISKKEDTPKEVA

SEQ ID NO: 2 -----
SEQ ID NO: 3 DVAEVQPKSSVTHNAETPKVRKARSVDEGSFDITRDSKNVVESTPITIQGKEHFEGYGSV

SEQ ID NO: 2 -----
SEQ ID NO: 3 DIQKKPTDLGVSEVTRFNVGNESNGLIGALQLKNKIDFSKDFNFKVRVANNHQSNTTGAD

SEQ ID NO: 2 -----
SEQ ID NO: 3 GWGFLFSKGNABEYLTNGGILGDKGLVNSGGFKIDTGYIYTSSMDKTEKQAGQGYRGYA

SEQ ID NO: 2 -----
SEQ ID NO: 3 FVKNDSSGNSQMVGENIDKSKTNFLNYADNSTNTSDGKFHGQRLNDVILTYVASTGKMRA

SEQ ID NO: 2 HHHHHSSGLVPRGSGMKETAAAKFERQHMDSPDLGTDDDDKAMGRDLDKGSEFTFTPEAP
SEQ ID NO: 3 EYAGKTWETSITDLGLSKNQAYNFLITSSQRWGLNQGINANGWMRTDLKGSEFTFTPEAP

SEQ ID NO: 2 KTITELEKKVEEIPFKKERKFNPDLAPGTEKVTREGQKGEKTITTTPTLKNPLTGVIISKG
SEQ ID NO: 3 KTITELEKKVEEIPFKKERKFNPDLAPGTEKVTREGQKGEKTITTTPTLKNPLTGVIISKG

SEQ ID NO: 2 EPKEEITKDPINELTEYGPETIAPGHRDEFDPKLPTGEKEEVPKGKPGIKNPETGDVVRPP
SEQ ID NO: 3 EPKEEITKDPINELTEYGPETIAPGHRDEFDPKLPTGEKEEVPKGKPGIKNPETGDVVRPP

SEQ ID NO: 2 VDSVTKYGPVKGDSIVEKEEIPFEKERKFNPDLAPGTEKVTREGQKGEKTITT-----
SEQ ID NO: 3 VDSVTKYGPVKGDSIVEKEEIPFEKERKFNPDLAPGTEKVTREGQKGEKTITTTPTLKNPL

SEQ ID NO: 2 -----
SEQ ID NO: 3 TGVIISKGEPKEEITKDPINELTEYGPETITPGHRDEFDPKLPTGEKEEVPKGKPGIKNPE

SEQ ID NO: 2 -----
SEQ ID NO: 3 TGDVVRPPVDSVTKYGPVKGDSIVEKEEIPFKKERKFNPDLAPGTEKVTREGQKGEKTIT

SEQ ID NO: 2 -----
SEQ ID NO: 3 TPTLKNPLTGEIISKGESKEEITKDPINELTEYGPETITPGHRDEFDPKLPTGEKEEVPG

SEQ ID NO: 2 -----
SEQ ID NO: 3 KPGIKNPETGDVVRPPVDSVTKYGPVKGDSIVEKEEIPFKKERKFNPDLAPGTEKVTREG

SEQ ID NO: 2 -----
SEQ ID NO: 3 QKGEKTITTTPTLKNPLTGEIISKGESKEEITKDPINELTEYGPETITPGHRDEFDPKLPT

SEQ ID NO: 2 -----
SEQ ID NO: 3 GEKEEVPKGKPGIKNPETGDVVRPPVDSVTKYGPVKGDSIVEKEEIPFEKERKFNPDLAPG

SEQ ID NO: 2 -----
SEQ ID NO: 3 TEKVTREGQKGEKTITTTPTLKNPLTGEIISKGESKEEITKDPVNELTEFGGEKIPQGHKD

SEQ ID NO: 2 -----
SEQ ID NO: 3 IFDPNLPDQTEKVPKGKPGIKNPDTGKVIEEPVDDVIKHGPKTGTPTETKTVEIPFETKRE

SEQ ID NO: 2 -----
SEQ ID NO: 3 FNPKLQPGEEVRVKQEGQPGSKTITTPITVNPLTGEKVGEGQPTTEEITKQPVDKIVEFGGE

SEQ ID NO: 2 -----
SEQ ID NO: 3 KPKDPKGPENPEKPSRPTHPSGPVNPNNPGLSKDRAKPNGPVHSMKNDKVKSKIAKES

SEQ ID NO: 2 -----
SEQ ID NO: 3 VANQEKKRAELPKTGLESTQKGLIFSSIIGIAGLMLLARRRKN

```

FIG. 2

3/4




FIG. 3

4/4

MGNKQQKEFKSFYSIRKSSLGVASVAISTLLLLMSNGEAQAAAAEETGGTNTEAQPKEAVASPTTTSEKAPETKP
VANAVSVSNKEVEAPTSETKEAKEVKEVKAPKETKEVKPAKATNNTYPILNQELREAIKNPAIKDKDHSAPNSR
PIDFEMKKKDGTTQQFYHYASSVKPARVIFTDSKPEIELGLQSGQFWRKFEVYEGDKKLPIKLVSYDTVYAYIR
FSVSNGTKAVKIVSSTHFNNKEEKYDYTLMEFAQPIYNSADKFKTEEDYKAEKLLAPYKKAKTLERQVYELNKIQ
DKLPEKLKAEYKKKLEDTKKALDEQVKSATIEFQNVQPTNEKMTDLQDTKYVVYESVENNESMMDTFVKHPIKTG
MLNGKKYVMETTNDDYWKDFMVEGQVRVTISKDAKNNRTIIFPYVEGKTLYDAIVKVHVKTIDYDGQYHVRIV
DKEAFTKANTDKSNKKEQQDNSAKKEATPATPSKPTPSPVEKESQKQDSQKDDNKQLPSVEKENDASSES GKDKT
PATKPTKGEVSSSTPTPKVVSTTQNVAKPTTASSKTTKDVVQTSAGSSEAKDSAPLQKANIKNNTNDGHTQSQNN
KNTQENKAKSLPQTGEESNKDMTLPLMALLALSSIVAFVLPRKRKNLEHHHHHH

FIG. 4

ATGCACCATCATCATCATCATCTTCTTCTGGTCTGGTGCCACGCGGTTCTGGTATGAAAGAAACCGCTGCTGCTAAA
TTCGAACGCCAGCACATGGACAGCCCAGATCTGGGTACCGACGACGACGACAAGGCC**ATGGGC**GAGAACTGACTTG
AAAGGTTTCAAGAGTTTACTTTTACACCAGAAGCGCCAAAAACAATAACAGAATTAGAAAAAAAGTTGAAGAGATT
CCATTCAAGAAAGAACGTAAATTTAATCCGGATTTAGCACCAGGGACAGAAAAAGTAACAAGAGAAGGACAAAAA
GGTGAGAAGACAATAACGACACCAACACTAAAAAATCCATTAACTGGAGTAATTATTAGTAAAGGTGAACCAAAA
GAAGAGATTACAAAAGATCCGATTAATGAATTAACAGAATACGGACCTGAAACAATAGCGCCAGGTCATCGAGAC
GAATTTGATCCGAAGTTACCAACAGGAGAGAGAAAGAGGAAGTTCCAGGTAAACCAGGAATTAAGAATCCAGAAACA
GGAGACGTAGTTAGACCGCCGGTCGATAGCGTAACAAAATATGGACCTGTAAAAGGAGACTCGATTGTAGAAAAA
GAAGAGATTCCATTGAGAGAAAGAACGTAAATTTAATCCGGATTTAGCACCAGGGACAGAAAAAGTAACAAGAGAA
GGACAAAAAGGTGAGAAGACAATAACGACAT**TAA**

FIG. 5

SEQUENCE LISTING

<110> Merck & Co., Inc.

<120> POLYPEPTIDES FOR INDUCING A PROTECTIVE
IMMUNE RESPONSE AGAINST STAPHYLOCOCCUS AUREUS

<130> 21491Y PCT

<150> 60/548,660

<151> 2004-02-27

<160> 9

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 189

<212> PRT

<213> Artificial Sequence

<220>

<223> truncated derivative of ORF0594

<400> 1

Arg	Thr	Asp	Leu	Lys	Gly	Ser	Glu	Phe	Thr	Phe	Thr	Pro	Glu	Ala	Pro
1				5					10					15	
Lys	Thr	Ile	Thr	Glu	Leu	Glu	Lys	Lys	Val	Glu	Glu	Ile	Pro	Phe	Lys
			20					25					30		
Lys	Glu	Arg	Lys	Phe	Asn	Pro	Asp	Leu	Ala	Pro	Gly	Thr	Glu	Lys	Val
			35				40					45			
Thr	Arg	Glu	Gly	Gln	Lys	Gly	Glu	Lys	Thr	Ile	Thr	Thr	Pro	Thr	Leu
			50			55				60					
Lys	Asn	Pro	Leu	Thr	Gly	Val	Ile	Ile	Ser	Lys	Gly	Glu	Pro	Lys	Glu
65					70				75					80	
Glu	Ile	Thr	Lys	Asp	Pro	Ile	Asn	Glu	Leu	Thr	Glu	Tyr	Gly	Pro	Glu
			85					90					95		
Thr	Ile	Ala	Pro	Gly	His	Arg	Asp	Glu	Phe	Asp	Pro	Lys	Leu	Pro	Thr
			100					105					110		
Gly	Glu	Lys	Glu	Glu	Val	Pro	Gly	Lys	Pro	Gly	Ile	Lys	Asn	Pro	Glu
			115				120					125			
Thr	Gly	Asp	Val	Val	Arg	Pro	Pro	Val	Asp	Ser	Val	Thr	Lys	Tyr	Gly
			130			135					140				
Pro	Val	Lys	Gly	Asp	Ser	Ile	Val	Glu	Lys	Glu	Glu	Ile	Pro	Phe	Glu
145				150					155					160	
Lys	Glu	Arg	Lys	Phe	Asn	Pro	Asp	Leu	Ala	Pro	Gly	Thr	Glu	Lys	Val
			165					170						175	
Thr	Arg	Glu	Gly	Gln	Lys	Gly	Glu	Lys	Thr	Ile	Thr	Thr			
			180					185							

<210> 2

<211> 235

<212> PRT

<213> Artificial Sequence

<220>

<223> His-tagged derivative of SEQ ID NO: 1

<400> 2

```

Met His His His His His His Ser Ser Gly Leu Val Pro Arg Gly Ser
 1          5          10          15
Gly Met Lys Glu Thr Ala Ala Ala Lys Phe Glu Arg Gln His Met Asp
      20          25          30
Ser Pro Asp Leu Gly Thr Asp Asp Asp Asp Lys Ala Met Gly Arg Thr
      35          40          45
Asp Leu Lys Gly Ser Glu Phe Thr Phe Thr Pro Glu Ala Pro Lys Thr
 50          55          60
Ile Thr Glu Leu Glu Lys Lys Val Glu Glu Ile Pro Phe Lys Lys Glu
65          70          75          80
Arg Lys Phe Asn Pro Asp Leu Ala Pro Gly Thr Glu Lys Val Thr Arg
      85          90          95
Glu Gly Gln Lys Gly Glu Lys Thr Ile Thr Thr Pro Thr Leu Lys Asn
      100          105          110
Pro Leu Thr Gly Val Ile Ile Ser Lys Gly Glu Pro Lys Glu Glu Ile
      115          120          125
Thr Lys Asp Pro Ile Asn Glu Leu Thr Glu Tyr Gly Pro Glu Thr Ile
      130          135          140
Ala Pro Gly His Arg Asp Glu Phe Asp Pro Lys Leu Pro Thr Gly Glu
145          150          155          160
Lys Glu Glu Val Pro Gly Lys Pro Gly Ile Lys Asn Pro Glu Thr Gly
      165          170          175
Asp Val Val Arg Pro Pro Val Asp Ser Val Thr Lys Tyr Gly Pro Val
      180          185          190
Lys Gly Asp Ser Ile Val Glu Lys Glu Glu Ile Pro Phe Glu Lys Glu
      195          200          205
Arg Lys Phe Asn Pro Asp Leu Ala Pro Gly Thr Glu Lys Val Thr Arg
      210          215          220
Glu Gly Gln Lys Gly Glu Lys Thr Ile Thr Thr
225          230          235

```

<210> 3

<211> 1240

<212> PRT

<213> *S. aureus*

<400> 3

```

Met Arg Asp Lys Lys Gly Pro Val Asn Lys Arg Val Asp Phe Leu Ser
 1          5          10          15
Asn Lys Leu Asn Lys Tyr Ser Ile Arg Lys Phe Thr Val Gly Thr Ala
      20          25          30
Ser Ile Leu Ile Gly Ser Leu Met Tyr Leu Gly Thr Gln Gln Glu Ala
      35          40          45
Glu Ala Ala Glu Asn Asn Ile Glu Asn Pro Thr Thr Leu Lys Asp Asn
 50          55          60
Val Gln Ser Lys Glu Val Lys Ile Glu Glu Val Thr Asn Lys Asp Thr
65          70          75          80
Ala Pro Gln Gly Val Glu Ala Lys Ser Glu Val Thr Ser Asn Lys Asp
      85          90          95
Thr Ile Glu His Glu Pro Ser Val Lys Ala Glu Asp Ile Ser Lys Lys
      100          105          110

```

Glu	Asp	Thr	Pro	Lys	Glu	Val	Ala	Asp	Val	Ala	Glu	Val	Gln	Pro	Lys	115	120	125
Ser	Ser	Val	Thr	His	Asn	Ala	Glu	Thr	Pro	Lys	Val	Arg	Lys	Ala	Arg	130	135	140
Ser	Val	Asp	Glu	Gly	Ser	Phe	Asp	Ile	Thr	Arg	Asp	Ser	Lys	Asn	Val	145	150	155
Val	Glu	Ser	Thr	Pro	Ile	Thr	Ile	Gln	Gly	Lys	Glu	His	Phe	Glu	Gly	165	170	175
Tyr	Gly	Ser	Val	Asp	Ile	Gln	Lys	Lys	Pro	Thr	Asp	Leu	Gly	Val	Ser	180	185	190
Glu	Val	Thr	Arg	Phe	Asn	Val	Gly	Asn	Glu	Ser	Asn	Gly	Leu	Ile	Gly	195	200	205
Ala	Leu	Gln	Leu	Lys	Asn	Lys	Ile	Asp	Phe	Ser	Lys	Asp	Phe	Asn	Phe	210	215	220
Lys	Val	Arg	Val	Ala	Asn	Asn	His	Gln	Ser	Asn	Thr	Thr	Gly	Ala	Asp	225	230	235
Gly	Trp	Gly	Phe	Leu	Phe	Ser	Lys	Gly	Asn	Ala	Glu	Glu	Tyr	Leu	Thr	245	250	255
Asn	Gly	Gly	Ile	Leu	Gly	Asp	Lys	Gly	Leu	Val	Asn	Ser	Gly	Gly	Phe	260	265	270
Lys	Ile	Asp	Thr	Gly	Tyr	Ile	Tyr	Thr	Ser	Ser	Met	Asp	Lys	Thr	Glu	275	280	285
Lys	Gln	Ala	Gly	Gln	Gly	Tyr	Arg	Gly	Tyr	Gly	Ala	Phe	Val	Lys	Asn	290	295	300
Asp	Ser	Ser	Gly	Asn	Ser	Gln	Met	Val	Gly	Glu	Asn	Ile	Asp	Lys	Ser	305	310	315
Lys	Thr	Asn	Phe	Leu	Asn	Tyr	Ala	Asp	Asn	Ser	Thr	Asn	Thr	Ser	Asp	325	330	335
Gly	Lys	Phe	His	Gly	Gln	Arg	Leu	Asn	Asp	Val	Ile	Leu	Thr	Tyr	Val	340	345	350
Ala	Ser	Thr	Gly	Lys	Met	Arg	Ala	Glu	Tyr	Ala	Gly	Lys	Thr	Trp	Glu	355	360	365
Thr	Ser	Ile	Thr	Asp	Leu	Gly	Leu	Ser	Lys	Asn	Gln	Ala	Tyr	Asn	Phe	370	375	380
Leu	Ile	Thr	Ser	Ser	Gln	Arg	Trp	Gly	Leu	Asn	Gln	Gly	Ile	Asn	Ala	385	390	395
Asn	Gly	Trp	Met	Arg	Thr	Asp	Leu	Lys	Gly	Ser	Glu	Phe	Thr	Phe	Thr	405	410	415
Pro	Glu	Ala	Pro	Lys	Thr	Ile	Thr	Glu	Leu	Glu	Lys	Lys	Val	Glu	Glu	420	425	430
Ile	Pro	Phe	Lys	Lys	Glu	Arg	Lys	Phe	Asn	Pro	Asp	Leu	Ala	Pro	Gly	435	440	445
Thr	Glu	Lys	Val	Thr	Arg	Glu	Gly	Gln	Lys	Gly	Glu	Lys	Thr	Ile	Thr	450	455	460
Thr	Pro	Thr	Leu	Lys	Asn	Pro	Leu	Thr	Gly	Val	Ile	Ile	Ser	Lys	Gly	465	470	475
Glu	Pro	Lys	Glu	Glu	Ile	Thr	Lys	Asp	Pro	Ile	Asn	Glu	Leu	Thr	Glu	485	490	495
Tyr	Gly	Pro	Glu	Thr	Ile	Ala	Pro	Gly	His	Arg	Asp	Glu	Phe	Asp	Pro	500	505	510
Lys	Leu	Pro	Thr	Gly	Glu	Lys	Glu	Glu	Val	Pro	Gly	Lys	Pro	Gly	Ile	515	520	525
Lys	Asn	Pro	Glu	Thr	Gly	Asp	Val	Val	Arg	Pro	Pro	Val	Asp	Ser	Val	530	535	540

Thr	Lys	Tyr	Gly	Pro	Val	Lys	Gly	Asp	Ser	Ile	Val	Glu	Lys	Glu	Glu
545					550					555					560
Ile	Pro	Phe	Glu	Lys	Glu	Arg	Lys	Phe	Asn	Pro	Asp	Leu	Ala	Pro	Gly
				565					570						575
Thr	Glu	Lys	Val	Thr	Arg	Glu	Gly	Gln	Lys	Gly	Glu	Lys	Thr	Ile	Thr
			580					585					590		
Thr	Pro	Thr	Leu	Lys	Asn	Pro	Leu	Thr	Gly	Val	Ile	Ile	Ser	Lys	Gly
		595					600					605			
Glu	Pro	Lys	Glu	Glu	Ile	Thr	Lys	Asp	Pro	Ile	Asn	Glu	Leu	Thr	Glu
	610					615					620				
Tyr	Gly	Pro	Glu	Thr	Ile	Thr	Pro	Gly	His	Arg	Asp	Glu	Phe	Asp	Pro
625					630					635					640
Lys	Leu	Pro	Thr	Gly	Glu	Lys	Glu	Glu	Val	Pro	Gly	Lys	Pro	Gly	Ile
				645					650						655
Lys	Asn	Pro	Glu	Thr	Gly	Asp	Val	Val	Arg	Pro	Pro	Val	Asp	Ser	Val
			660					665					670		
Thr	Lys	Tyr	Gly	Pro	Val	Lys	Gly	Asp	Ser	Ile	Val	Glu	Lys	Glu	Glu
			675				680						685		
Ile	Pro	Phe	Lys	Lys	Glu	Arg	Lys	Phe	Asn	Pro	Asp	Leu	Ala	Pro	Gly
	690					695					700				
Thr	Glu	Lys	Val	Thr	Arg	Glu	Gly	Gln	Lys	Gly	Glu	Lys	Thr	Ile	Thr
705					710					715					720
Thr	Pro	Thr	Leu	Lys	Asn	Pro	Leu	Thr	Gly	Glu	Ile	Ile	Ser	Lys	Gly
				725					730						735
Glu	Ser	Lys	Glu	Glu	Ile	Thr	Lys	Asp	Pro	Ile	Asn	Glu	Leu	Thr	Glu
			740					745					750		
Tyr	Gly	Pro	Glu	Thr	Ile	Thr	Pro	Gly	His	Arg	Asp	Glu	Phe	Asp	Pro
		755					760					765			
Lys	Leu	Pro	Thr	Gly	Glu	Lys	Glu	Glu	Val	Pro	Gly	Lys	Pro	Gly	Ile
	770					775					780				
Lys	Asn	Pro	Glu	Thr	Gly	Asp	Val	Val	Arg	Pro	Pro	Val	Asp	Ser	Val
785					790					795					800
Thr	Lys	Tyr	Gly	Pro	Val	Lys	Gly	Asp	Ser	Ile	Val	Glu	Lys	Glu	Glu
				805					810						815
Ile	Pro	Phe	Lys	Lys	Glu	Arg	Lys	Phe	Asn	Pro	Asp	Leu	Ala	Pro	Gly
			820					825					830		
Thr	Glu	Lys	Val	Thr	Arg	Glu	Gly	Gln	Lys	Gly	Glu	Lys	Thr	Ile	Thr
		835					840					845			
Thr	Pro	Thr	Leu	Lys	Asn	Pro	Leu	Thr	Gly	Glu	Ile	Ile	Ser	Lys	Gly
	850					855					860				
Glu	Ser	Lys	Glu	Glu	Ile	Thr	Lys	Asp	Pro	Ile	Asn	Glu	Leu	Thr	Glu
865					870					875					880
Tyr	Gly	Pro	Glu	Thr	Ile	Thr	Pro	Gly	His	Arg	Asp	Glu	Phe	Asp	Pro
				885					890						895
Lys	Leu	Pro	Thr	Gly	Glu	Lys	Glu	Glu	Val	Pro	Gly	Lys	Pro	Gly	Ile
			900					905					910		
Lys	Asn	Pro	Glu	Thr	Gly	Asp	Val	Val	Arg	Pro	Pro	Val	Asp	Ser	Val
		915					920						925		
Thr	Lys	Tyr	Gly	Pro	Val	Lys	Gly	Asp	Ser	Ile	Val	Glu	Lys	Glu	Glu
	930					935					940				
Ile	Pro	Phe	Glu	Lys	Glu	Arg	Lys	Phe	Asn	Pro	Asp	Leu	Ala	Pro	Gly
945					950					955					960
Thr	Glu	Lys	Val	Thr	Arg	Glu	Gly	Gln	Lys	Gly	Glu	Lys	Thr	Ile	Thr
				965					970						975

```

Thr Pro Thr Leu Lys Asn Pro Leu Thr Gly Glu Ile Ile Ser Lys Gly
      980                      985                      990
Glu Ser Lys Glu Glu Ile Thr Lys Asp Pro Val Asn Glu Leu Thr Glu
      995                      1000                      1005
Phe Gly Gly Glu Lys Ile Pro Gln Gly His Lys Asp Ile Phe Asp Pro
      1010                      1015                      1020
Asn Leu Pro Thr Asp Gln Thr Glu Lys Val Pro Gly Lys Pro Gly Ile
      1025                      1030                      1035                      1040
Lys Asn Pro Asp Thr Gly Lys Val Ile Glu Glu Pro Val Asp Asp Val
      1045                      1050                      1055
Ile Lys His Gly Pro Lys Thr Gly Thr Pro Glu Thr Lys Thr Val Glu
      1060                      1065                      1070
Ile Pro Phe Glu Thr Lys Arg Glu Phe Asn Pro Lys Leu Gln Pro Gly
      1075                      1080                      1085
Glu Glu Arg Val Lys Gln Glu Gly Gln Pro Gly Ser Lys Thr Ile Thr
      1090                      1095                      1100
Thr Pro Ile Thr Val Asn Pro Leu Thr Gly Glu Lys Val Gly Glu Gly
      1105                      1110                      1115                      1120
Gln Pro Thr Glu Glu Ile Thr Lys Gln Pro Val Asp Lys Ile Val Glu
      1125                      1130                      1135
Phe Gly Gly Glu Lys Pro Lys Asp Pro Lys Gly Pro Glu Asn Pro Glu
      1140                      1145                      1150
Lys Pro Ser Arg Pro Thr His Pro Ser Gly Pro Val Asn Pro Asn Asn
      1155                      1160                      1165
Pro Gly Leu Ser Lys Asp Arg Ala Lys Pro Asn Gly Pro Val His Ser
      1170                      1175                      1180
Met Asp Lys Asn Asp Lys Val Lys Lys Ser Lys Ile Ala Lys Glu Ser
      1185                      1190                      1195                      1200
Val Ala Asn Gln Glu Lys Lys Arg Ala Glu Leu Pro Lys Thr Gly Leu
      1205                      1210                      1215
Glu Ser Thr Gln Lys Gly Leu Ile Phe Ser Ser Ile Ile Gly Ile Ala
      1220                      1225                      1230
Gly Leu Met Leu Leu Ala Arg Arg
      1235                      1240

```

<210> 4
 <211> 654
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> immunogen

```

<400> 4
Met Gly Asn Lys Gln Gln Lys Glu Phe Lys Ser Phe Tyr Ser Ile Arg
  1           5           10           15
Lys Ser Ser Leu Gly Val Ala Ser Val Ala Ile Ser Thr Leu Leu Leu
      20           25           30
Leu Met Ser Asn Gly Glu Ala Gln Ala Ala Ala Glu Glu Thr Gly Gly
      35           40           45
Thr Asn Thr Glu Ala Gln Pro Lys Thr Glu Ala Val Ala Ser Pro Thr
      50           55           60
Thr Thr Ser Glu Lys Ala Pro Glu Thr Lys Pro Val Ala Asn Ala Val
      65           70           75           80

```

Ser	Val	Ser	Asn	Lys	Glu	Val	Glu	Ala	Pro	Thr	Ser	Glu	Thr	Lys	Glu	
				85					90					95		
Ala	Lys	Glu	Val	Lys	Glu	Val	Lys	Ala	Pro	Lys	Glu	Thr	Lys	Glu	Val	
			100					105					110			
Lys	Pro	Ala	Ala	Lys	Ala	Thr	Asn	Asn	Thr	Tyr	Pro	Ile	Leu	Asn	Gln	
		115					120					125				
Glu	Leu	Arg	Glu	Ala	Ile	Lys	Asn	Pro	Ala	Ile	Lys	Asp	Lys	Asp	His	
	130					135					140					
Ser	Ala	Pro	Asn	Ser	Arg	Pro	Ile	Asp	Phe	Glu	Met	Lys	Lys	Lys	Asp	
145					150					155					160	
Gly	Thr	Gln	Gln	Phe	Tyr	His	Tyr	Ala	Ser	Ser	Val	Lys	Pro	Ala	Arg	
				165					170					175		
Val	Ile	Phe	Thr	Asp	Ser	Lys	Pro	Glu	Ile	Glu	Leu	Gly	Leu	Gln	Ser	
			180					185					190			
Gly	Gln	Phe	Trp	Arg	Lys	Phe	Glu	Val	Tyr	Glu	Gly	Asp	Lys	Lys	Leu	
		195					200					205				
Pro	Ile	Lys	Leu	Val	Ser	Tyr	Asp	Thr	Val	Lys	Asp	Tyr	Ala	Tyr	Ile	
	210					215					220					
Arg	Phe	Ser	Val	Ser	Asn	Gly	Thr	Lys	Ala	Val	Lys	Ile	Val	Ser	Ser	
225					230					235					240	
Thr	His	Phe	Asn	Asn	Lys	Glu	Glu	Lys	Tyr	Asp	Tyr	Thr	Leu	Met	Glu	
				245					250					255		
Phe	Ala	Gln	Pro	Ile	Tyr	Asn	Ser	Ala	Asp	Lys	Phe	Lys	Thr	Glu	Glu	
			260					265					270			
Asp	Tyr	Lys	Ala	Glu	Lys	Leu	Leu	Ala	Pro	Tyr	Lys	Lys	Ala	Lys	Thr	
	275						280					285				
Leu	Glu	Arg	Gln	Val	Tyr	Glu	Leu	Asn	Lys	Ile	Gln	Asp	Lys	Leu	Pro	
	290					295					300					
Glu	Lys	Leu	Lys	Ala	Glu	Tyr	Lys	Lys	Lys	Leu	Glu	Asp	Thr	Lys	Lys	
305					310					315					320	
Ala	Leu	Asp	Glu	Gln	Val	Lys	Ser	Ala	Ile	Thr	Glu	Phe	Gln	Asn	Val	
				325					330					335		
Gln	Pro	Thr	Asn	Glu	Lys	Met	Thr	Asp	Leu	Gln	Asp	Thr	Lys	Tyr	Val	
			340					345					350			
Val	Tyr	Glu	Ser	Val	Glu	Asn	Asn	Glu	Ser	Met	Met	Asp	Thr	Phe	Val	
		355					360					365				
Lys	His	Pro	Ile	Lys	Thr	Gly	Met	Leu	Asn	Gly	Lys	Lys	Tyr	Met	Val	
	370					375					380					
Met	Glu	Thr	Thr	Asn	Asp	Asp	Tyr	Trp	Lys	Asp	Phe	Met	Val	Glu	Gly	
385					390					395					400	
Gln	Arg	Val	Arg	Thr	Ile	Ser	Lys	Asp	Ala	Lys	Asn	Asn	Thr	Arg	Thr	
				405					410					415		
Ile	Ile	Phe	Pro	Tyr	Val	Glu	Gly	Lys	Thr	Leu	Tyr	Asp	Ala	Ile	Val	
			420					425					430			
Lys	Val	His	Val	Lys	Thr	Ile	Asp	Tyr	Asp	Gly	Gln	Tyr	His	Val	Arg	
		435					440					445				
Ile	Val	Asp	Lys	Glu	Ala	Phe	Thr	Lys	Ala	Asn	Thr	Asp	Lys	Ser	Asn	
	450					455					460					
Lys	Lys	Glu	Gln	Gln	Asp	Asn	Ser	Ala	Lys	Lys	Glu	Ala	Thr	Pro	Ala	
465					470					475					480	
Thr	Pro	Ser	Lys	Pro	Thr	Pro	Ser	Pro	Val	Glu	Lys	Glu	Ser	Gln	Lys	
				485					490					495		
Gln	Asp	Ser	Gln	Lys	Asp	Asp	Asn	Lys	Gln	Leu	Pro	Ser	Val	Glu	Lys	
			500					505					510			

Glu Asn Asp Ala Ser Ser Glu Ser Gly Lys Asp Lys Thr Pro Ala Thr
 515 520 525
 Lys Pro Thr Lys Gly Glu Val Glu Ser Ser Ser Thr Thr Pro Thr Lys
 530 535 540
 Val Val Ser Thr Thr Gln Asn Val Ala Lys Pro Thr Thr Ala Ser Ser
 545 550 555 560
 Lys Thr Thr Lys Asp Val Val Gln Thr Ser Ala Gly Ser Ser Glu Ala
 565 570 575
 Lys Asp Ser Ala Pro Leu Gln Lys Ala Asn Ile Lys Asn Thr Asn Asp
 580 585 590
 Gly His Thr Gln Ser Gln Asn Asn Lys Asn Thr Gln Glu Asn Lys Ala
 595 600 605
 Lys Ser Leu Pro Gln Thr Gly Glu Glu Ser Asn Lys Asp Met Thr Leu
 610 615 620
 Pro Leu Met Ala Leu Leu Ala Leu Ser Ser Ile Val Ala Phe Val Leu
 625 630 635 640
 Pro Arg Lys Arg Lys Asn Leu Glu His His His His His
 645 650

<210> 5
 <211> 708
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> nucleic acid encoding SEQ ID NO: 2

<400> 5
 atgcaccatc atcatcatca ttcttctggt ctggtgccac gcggttctgg tatgaaagaa 60
 accgctgctg ctaaattcga acgccagcac atggacagcc cagatctggg taccgacgac 120
 gacgacaagg ccatgggcag aactgacttg aaagggttcag agtttacttt tacaccagaa 180
 gcgccaaaaa caataacaga attagaaaaa aaagttgaag agattccatt caagaaagaa 240
 cgtaaattta atccggattt agcaccaggg acagaaaaag taacaagaga aggacaaaaa 300
 ggtgagaaga caataacgac accaactacta aaaaatccat taactggagt aattattagt 360
 aaaggtgaac caaaagaaga gattacaaaa gatccgatta atgaattaac agaatacggg 420
 cctgaaacaa tagcgccagg tcatcgagac gaatttgatc cgaagttacc aacaggagag 480
 aaagaggaag ttccaggtaa accaggaatt aagaatccag aaacaggaga cgtagttaga 540
 ccgccggtcg atagcgtaac aaaatatgga cctgtaaaag gagactcgat tgtagaaaaa 600
 gaagagattc cattcgagaa agaacgtaaa tttaatccgg atttagcacc agggacagaa 660
 aaagtaacaa gagaaggaca aaaaggtgag aagacaataa cgacataa 708

<210> 6
 <211> 34
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> primer

<400> 6
 accggttcca tatgagagat aagaaaggac cgggt

34

<210> 7
 <211> 40
 <212> DNA

<213> Artificial Sequence

<220>

<223> primer

<400> 7

ccggcggccc tcgagattct ttcttctacg agccaataac

40

<210> 8

<211> 39

<212> DNA

<213> Artificial Sequence

<220>

<223> primer

<400> 8

gagatatacc atgggcagaa ctgacttgaa aggttcaga

39

<210> 9

<211> 40

<212> DNA

<213> Artificial Sequence

<220>

<223> primer

<400> 9

ccggcggccc tcgagttatg tcgttattgt cttctcacct

40